# CYB003 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cyb003

> The next catalyst for CYB003, sponsored by Helus Pharma Inc. (HELP), is its topline data readout, June 30, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for CYB003?

The next catalyst for CYB003, sponsored by Helus Pharma Inc. (HELP), is its topline data readout, June 30, 2027. Press release filed with the SEC (EX-99): "Each Warrant will be exercisable to acquire one Common Share at a price of US$8.14 per Common Share at any time prior to the earlier of: (i) June 30, 2027; (ii) thirty days following the publication by press release of topline data for the APPROACH trial of CYB003 in major depressive disorder; and (iii) thirty days following the date a press release is issued by the Company announcing exercise of its acceleration right, which right can only be exercised if the closing price of the Common Share on NYSE American LLC (the "NYSE American") is equal to or exceeds US$19.53 per Common Share for any five consecutive trading days." [Calendar and source filings](https://sec-api.dev/pdufa/cyb003)

Source: Press release filed with the SEC (EX-99), accession 0001833141-25-000046, https://www.sec.gov/Archives/edgar/data/1833141/000183314125000046/materialchangereportcybin-.htm (retrieved 2026-11-12). Last confirmed 2025-11-26. Cite: https://sec-api.dev/pdufa/cyb003#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | CYB003 |
| Codes | CYB003 |
| Sponsor | Helus Pharma Inc. (HELP) https://sec-api.dev/companies/help/catalysts |
| Indications | [moderate to severe mdd](https://sec-api.dev/indications/moderate-to-severe-mdd), [generalized anxiety disorder](https://sec-api.dev/indications/generalized-anxiety-disorder), mdd and other mental health conditions, mdd in november 2024 |
| Modality |  |
| FDA designations | breakthrough |

## Timeline

### October 31, 2023: interim data readout

- Status: completed, met. Date confidence: exact. Stage: 2. Indication: moderate to severe MDD.
- First seen 2024-11-13, last confirmed 2025-11-13.
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000043): "On October 31, 2023, the Company announced Phase 2a interim results for CYB003, its proprietary deuterated psilocin molecule, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo, in participants with moderate to severe MDD." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000043/cybin-mdaxq2x26.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000007): "On October 31, 2023, the Company announced Phase 2a interim results for CYB003, its proprietary deuterated psilocin molecule, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo, in participants with moderate to severe MDD." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000007/cybin-mdaxq1x26.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000001): "On October 31, 2023, the Company announced Phase 2a interim results for CYB003, its proprietary deuterated psilocin analog, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo, in participants with moderate to severe MDD." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000001/cybin-mdaxq3x25xdecember31.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-24-000018): "On October 31, 2023, the Company announced Phase 2a interim results for CYB003, its proprietary deuterated psilocin analog, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12mg dose compared to placebo, in participants with moderate to severe MDD." https://www.sec.gov/Archives/edgar/data/1833141/000183314124000018/cybin-mdaxq2x25xseptember3.htm

### November 30, 2023: topline data readout

- Status: completed, met. Date confidence: exact. Stage: 2.
- First seen 2024-11-13, last confirmed 2025-11-13.
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000043): "On November 30, 2023, the Company announced positive Phase 2a topline results for CYB003, showing rapid and robust improvements in symptoms of depression after single doses of CYB003, with an average 14.1 point difference in MADRS score reduction between CYB003 and placebo which was statistically significant at 3 weeks (p<0.0001)." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000043/cybin-mdaxq2x26.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000007): "On November 30, 2023, the Company announced positive Phase 2a topline results for CYB003, showing rapid and robust improvements in symptoms of depression after single doses of CYB003, with an average 13.75 point difference in MADRS score reduction between CYB003 and placebo which was statistically significant at 3 weeks (p<0.0001)." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000007/cybin-mdaxq1x26.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000001): "On November 30, 2023, the Company announced positive Phase 2a topline results for CYB003, showing rapid and robust improvements in symptoms of depression after single doses of CYB003, with an average 13.75 point difference in MADRS score reduction between CYB003 and placebo which was statistically significant at 3 weeks (p<0.0001)." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000001/cybin-mdaxq3x25xdecember31.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-24-000018): "On November 30, 2023, the Company announced positive Phase 2a topline results for CYB003, showing rapid and robust improvements in symptoms of depression after single doses of CYB003, with an average 13.75 point difference in MADRS score reduction between CYB003 and placebo which was statistically significant at 3 weeks (p<0.0001)." https://www.sec.gov/Archives/edgar/data/1833141/000183314124000018/cybin-mdaxq2x25xseptember3.htm

### Nov 2024: trial start

- Status: scheduled. Date confidence: month. Stage: 3. Indication: MDD in November 2024.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0001833141-24-000018): "The Company anticipates to initiate a multinational Phase 3 study evaluating CYB003 in participants with MDD in November 2024.9" https://www.sec.gov/Archives/edgar/data/1833141/000183314124000018/cybin-mdaxq2x25xseptember3.htm

### Q1 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: generalized anxiety disorder.
- First seen 2024-11-18, last confirmed 2024-11-18.
- Press release filed with the SEC (EX-99) (accession 0001062993-24-019233): "Having aligned on trial design with the FDA, we recently initiated our Phase 3 PARADIGMTM pivotal program which will evaluate CYB003's efficacy and safety in a larger MDD population, and we expect to report Phase 2 topline results for CYB004, our proprietary deuterated dimethyltryptamine program for the treatment of generalized anxiety disorder, in the first quarter of 2025.1 We are committed to building on the positive clinical results to-date in both programs and to progressing CYB003 toward potential regulatory approval and commercialization," concluded Drysdale." https://www.sec.gov/Archives/edgar/data/1833141/000106299324019233/exhibit99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001062993-24-019233): "Forward-looking statements in this news release include statements regarding the Company's potential viability for treatment for patients with MDD and other mental health conditions; the Company's potential to impact the standard of care in MDD; the Company's ability to offer different treatment methods; the Company's ability to improve accessibility to treatment; the potential of CYB003 to change the course of disease; the Company's plans to report Phase 2 topline results for CYB004 in Q1 2025; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions." https://www.sec.gov/Archives/edgar/data/1833141/000106299324019233/exhibit99-1.htm

### mid-2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-05-08, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-023930): "Forward-looking statements in this news release include statements regarding the Company's expectations respecting the patent exclusivity period; commencement of the second Phase 3 study, EMBRACE, in mid-2025; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders." https://www.sec.gov/Archives/edgar/data/1833141/000162828025023930/a05-08x2025cyb003patentprf.htm

### 2026: topline data readout

- Status: scheduled. Date confidence: year.
- First seen 2025-01-13, last confirmed 2025-01-13.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-001391): "oAPPROACH has been initiated and will enroll 220 participants at 36 clinical sites across the U.S. and Europe; topline results expected in 2026 oEMBRACE will enroll 330 participants at sites across the U.S. and Europe and is expected to commence by mid 2025 oEXTEND is expected to begin 12 weeks after commencement of APPROACH and EMBRACE, respectively" https://www.sec.gov/Archives/edgar/data/1833141/000162828025001391/a01-13x2025cybnyearxendprf.htm

### June 30, 2027: topline data readout

- Status: scheduled. Date confidence: exact.
- First seen 2025-10-28, last confirmed 2025-11-26.
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000046): "Each Warrant will be exercisable to acquire one Common Share at a price of US$8.14 per Common Share at any time prior to the earlier of: (i) June 30, 2027; (ii) thirty days following the publication by press release of topline data for the APPROACH trial of CYB003 in major depressive disorder; and (iii) thirty days following the date a press release is issued by the Company announcing exercise of its acceleration right, which right can only be exercised if the closing price of the Common Share on NYSE American LLC (the "NYSE American") is equal to or exceeds US$19.53 per Common Share for any five consecutive trading days." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000046/materialchangereportcybin-.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-25-000027): "Each Warrant will be exercisable to acquire one Common Share at a price of US$8.14 per Common Share at any time prior to the earlier of: (i) June 30, 2027; (ii) thirty days following the publication by press release of topline data for the APPROACH trial of CYB003 in major depressive disorder; and (iii) thirty days following the date a press release is issued by the Company announcing exercise of its acceleration right, which right can only be exercised if the closing price of the Common Share on NYSE American LLC (the "NYSE American") is equal to or exceeds US$19.53 per Common Share for any five consecutive trading days." https://www.sec.gov/Archives/edgar/data/1833141/000183314125000027/finalpressreleaserelauncho.htm

## Same indication

- [CYB004](https://sec-api.dev/pdufa/cyb004) (HELP)
- [HLP003](https://sec-api.dev/pdufa/hlp003) (HELP)
- [GlyphAgo (SPT-320)](https://sec-api.dev/pdufa/spt-320) (PTCHF)

Calendar months: [June 2027](https://sec-api.dev/fda-calendar/2027-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cyb003.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CYB003 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cyb003

```bibtex
@misc{secapidev_pdufa_cyb003_20261116,
  title        = {CYB003 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cyb003}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cyb003_20261116","title":"CYB003 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cyb003","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
